Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Zbigniew Woznica

Internal Medicine Hartford, CT Medical Doctor

NPI 1174536486 CMS profile 235051

673 Maple Ave, Hartford, CT 06134

Open in the dashboard

General payments

$3,245

86 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Zbigniew Woznica of Hartford, CT is reported in the CMS Open Payments database as having received $3,245 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $117 1
2020 General $328 5
2019 General $2,800 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zbigniew Woznica
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Zbigniew Woznica were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Zbigniew Woznica Internal Medicine median Middle half National median
2019 $2,800 $159 $48–$570 $163
2020 $328 $119 $33–$402 $114
2021 $117 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Janssen Pharmaceuticals, Inc $713 14 payments
  2. Amgen Inc. $631 11 payments
  3. Novo Nordisk Inc $562 9 payments
  4. Allergan Inc. $369 10 payments
  5. Pfizer Inc. $164 5 payments
  6. Novartis Pharmaceuticals Corporation $164 3 payments
  7. Regeneron Healthcare Solutions, Inc. $135 2 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $124 11 payments
  9. Lilly USA, LLC $95 3 payments
  10. AstraZeneca Pharmaceuticals LP $71 5 payments
  11. Other $217 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,238 84 payments
  2. Education $8 2 payments
Products named General payments · program years 2019–2021
  1. Ozempic $535 7 payments
  2. Repatha $482 9 payments
  3. XARELTO $470 11 payments
  4. INVOKANA $358 10 payments
  5. LINZESS $223 4 payments
  6. ELIQUIS $164 5 payments
  7. ENTRESTO $164 3 payments
  8. AIMOVIG $142 2 payments
  9. PRALUENT $135 2 payments
  10. VRAYLAR $125 1 payment
  11. Other $1,030 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,597

Median for Internal Medicine: 777

Drug cost

$508,864

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 73 $75,888
Jardiance Empagliflozin Brand 49 $74,927
Januvia Sitagliptin Phosphate Brand 50 $69,764
Ozempic Semaglutide Brand 32 $41,744
Trulicity Dulaglutide Brand 27 $36,178
Tradjenta Linagliptin Brand 32 $35,145
Tresiba Flextouch U-100 Insulin Degludec Brand 31 $22,070
Mounjaro Tirzepatide Brand 11 $18,797
Farxiga Dapagliflozin Propanediol Brand 12 $18,395
Janumet Sitagliptin Phos/Metformin Hcl Brand 13 $10,763

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$42,313

Of which drugs: $6,321

Medicare patients

106

Average age 78

Services billed

1,148

55 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Chronic kidney disease 43%
Diabetes 33%
Arthritis 29%
Depression 23%
Atrial fibrillation 22%
Ischemic heart disease 21%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 20 20 $1,294

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record